Serono Rebif data review
Executive Summary
Data comparing Serono's Rebif and Biogen's Avonex in treatment of multiple sclerosis will be reviewed by FDA's Peripheral & Central Nervous System Drugs Advisory Committee Feb. 15. Serono is seeking to break Biogen's orphan exclusivity for interferon beta-1a in relapsing-remitting MS by demonstrating Rebif to be clinically superior to Avonex (1"The Pink Sheet" May 14, p. 9). The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m...